CoChat
Sign Up
Cited by 52Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Clinical and imaging correlates of amyloid deposition in dementia with Lewy bodies

Open access
Donaghy, Paul C., Firbank, Michael J, Thomas, Alan J., Lloyd, Jim, Petrides, George, Barnett, Nicola, Olsen, Kirsty, O'Brien, John T.·2018·Movement Disorders
DOI 10.1002/mds.27403PMC PMC6175485
Open this paper in CoChat — free accountOpen PDF

Abstract

Background : Amyloid deposition is common in dementia with Lewy bodies, but its pathophysiological significance is unclear. Objective : The objective of this study was to investigate the relationship between amyloid deposition and clinical profile, gray matter volume, and brain perfusion in dementia with Lewy bodies. Methods : Dementia with Lewy bodies (n = 37), Alzheimer's disease (n = 20), and controls (n = 20) underwent a thorough clinical assessment, 3T MRI, and early‐ and late‐phase 18 F‐Florbetapir PET‐CT to assess cortical perfusion and amyloid deposition, respectively. Amyloid scans were visually categorized as positive or negative. Image analysis was carried out using statistical parametric mapping (SPM) 8. Results : There were no significant differences between amyloid‐positive and amyloid‐negative dementia with Lewy bodies cases in age ( P = .78), overall cognitive impairment ( P = .83), level of functional impairment ( P = .80), or any other clinical or cognitive scale. There were also no significant differences in hippocampal or gray matter volumes. However, amyloid‐positive dementia with Lewy bodies cases had lower medial temporal lobe perfusion ( P = .03) than amyloid‐negative cases, although a combination of medial temporal lobe perfusion, hippocampal volume, and cognitive measures was unable to accurately predict amyloid status in dementia with Lewy bodies. Conclusions : Amyloid deposition was not associated with differences in clinical or neuropsychological profiles in dementia with Lewy bodies, but was associated with imaging evidence of medial temporal lobe dysfunction. The presence of amyloid in dementia with Lewy bodies cannot be identified on the basis of clinical and other imaging features and will require direct assessment via PET imaging or CSF. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.27403

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In DLB there are no clear differences in clinical symptoms and disease severity between amyloid PET positive and negative status.

    “In DLB there are no clear differences in clinical symptoms and disease severity between amyloid PET positive and negative status [175].”

    From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [175]

  • Brain imaging has improved understanding of the role of mixed pathologies in dementia.

    “Such imaging has also improved our understanding of the role of mixed pathologies in dementia [102, 175, 189, 247].”

    From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [175]

  • Brain imaging has helped improve the biological classification of AD by allowing proposed classifications based on pathology, like the ATN staging, to be applied in vivo and opened a new window of therapeutic intervention at preclinical stages.

    “Brain imaging has helped to improve the biological classification of AD by allowing proposed classifications based on pathology, like the ATN staging, to be applied in vivo and opened a new window of therapeutic intervention at preclinical stages.”

    From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [175]

    Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 41

  1. [1]McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12): 1863‐ 1872. 16237129
  2. [3]Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry 2015; 23(1): 23‐ 37. 23831180
  3. [4]Lin KJ, Hsiao IT, Hsu JL, et al. Imaging characteristic of dual‐phase (18)F‐Florbetapir (AV‐45/Amyvid) PET for the concomitant detection of perfusion deficits and beta‐amyloid deposition in Alzheimer's disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging 2016; 43(7): 1304‐ 1314. 27003417
  4. [5]McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3): 263‐ 269. 21514250 PMC3312024
  5. [6]McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89(1): 88‐ 100. 28592453 PMC5496518
  6. [8]Lambon RMA, Powell J, Howard D, Whitworth AB, Garrard P, Hodges JR. Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer's type: a comparative neuropsychological study and literature review. J Neurol Neurosurg Psychiatry 2001; 70(2): 149‐ 156. 11160461 PMC1737202
  7. [9]Sanchez‐Cubillo I, Perianez JA, Adrover‐Roig D, et al. Construct validity of the Trail Making Test: role of task‐switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc 2009; 15(3): 438‐ 450. 19402930
  8. [10]McKenna P, Warrington EK. Graded Naming Test: Object Picture Book. 2nd rev. ed. Cambridge: Cambridge Cognition Ltd; 2007.
  9. [12]Wood JS, Firbank MJ, Mosimann UP, et al. Testing visual perception in dementia with Lewy bodies and Alzheimer disease. Am J Geriatr Psychiatry 2013; 21(6): 501‐ 508. 23567415
  10. [13]Ballard C, O'Brien J, Gray A, et al. Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2001; 58(6): 977‐ 982. 11405813
  11. [14]Landy KM, Salmon DP, Galasko D, et al. Motion discrimination in dementia with Lewy bodies and Alzheimer disease. Neurology 2015; 85(16): 1376‐ 1382. 26400581 PMC4626245
  12. [15]Lawton MP, Brody EM. Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist 1969; 9(3): 179‐ 186. 5349366
  13. [16]Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996; 25(2): 113‐ 120. 8670538
  14. [17]D'Ath P, Katona P, Mullan E, Evans S, Katona C. Screening, detection and management of depression in elderly primary care attenders. I: the acceptability and performance of the 15 item Geriatric Depression Scale (GDS15) and the development of short versions. Fam Pract 1994; 11(3): 260‐ 266. 7843514
  15. [18]Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000; 177: 252‐ 256. 11040887
  16. [19]Lee DR, McKeith I, Mosimann U, et al. The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia. Am J Geriatr Psychiatry 2014; 22(9): 926‐ 935. 24332982
  17. [20]Cummings JL, Mega M, Gray K, Rosenberg‐Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44(12): 2308‐ 2314. 7991117
  18. [21]Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23(15): 2129‐ 2170. 19025984
  19. [23]Tzourio‐Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single‐subject brain. Neuroimage 2002; 15(1): 273‐ 289. 11771995
  20. [24]Jagust WJ, Landau SM, Koeppe RA, et al. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement 2015; 11(7): 757‐ 771. 26194311 PMC4510459
  21. [25]Della Rosa PA, Cerami C, Gallivanone F, et al. A standardized [18F]‐FDG‐PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 2014; 12(4): 575‐ 593. 24952892
  22. [26]O'Brien JT, Firbank MJ, Davison C, et al. 18F‐FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy Body dementias. J Nucl Med 2014; 55(12): 1959‐ 1965. 25453043
  23. [27]Firbank MJ, Barber R, Burton EJ, O'Brien JT. Validation of a fully automated hippocampal segmentation method on patients with dementia. Hum Brain Mapp 2008; 29(12): 1442‐ 1449. 17979118 PMC6871146
  24. [29]Halliday GM, Song YJ, Harding AJ. Striatal beta‐amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm 2011; 118(5): 713‐ 719. 21479514
  25. [31]Tiraboschi P, Attems J, Thomas A, et al. Clinicians' ability to diagnose dementia with Lewy bodies is not affected by beta‐amyloid load. Neurology 2015; 84(5): 496‐ 499. 25552579 PMC4336072
  26. [32]Nedelska Z, Ferman TJ, Boeve BF, et al. Pattern of brain atrophy rates in autopsy‐confirmed dementia with Lewy bodies. Neurobiol Aging 2015; 36(1): 452‐ 461. 25128280 PMC4268128
  27. [33]Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12(2): 207‐ 216. 23332364 PMC3622225
  28. [34]Abdelnour C, van Steenoven I, Londos E, et al. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Mov Disord 2016; 31(8): 1203‐ 1208. 27296778
  29. [35]Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy‐confirmed dementia with lewy bodies. Am J Psychiatry 2004; 161(5): 843‐ 849. 15121649
  30. [36]Gomperts SN, Locascio JJ, Makaretz SJ, et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol 2016; 73(11): 1334‐ 1341. 27654968 PMC5287290
  31. [37]Kantarci K, Lowe VJ, Boeve BF, et al. AV‐1451 tau and beta‐amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol 2017; 81(1): 58‐ 67. 27863444 PMC5299616
  32. [38]Ishii K, Hosokawa C, Hyodo T, et al. Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition. Ann Nucl Med 2015; 29(1): 78‐ 83. 25270712 PMC4835511
  33. [39]Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012; 33(9): 2091‐ 2105. 22018896 PMC3288845
  34. [40]Sarro L, Senjem ML, Lundt ES, et al. Amyloid‐beta deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain 2016; 139(Pt 10): 2740‐ 2750. 27452602 PMC5035818
  35. [41]Nedelska Z, Ferman TJ, Boeve BF, et al. Pattern of brain atrophy rates in autopsy‐confirmed dementia with Lewy bodies. Neurobiol Aging 2015; 36(1): 452– 61. 25128280 PMC4268128
  36. [42]Burton EJ, Barber R, Mukaetova‐Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009; 132(Pt 1): 195‐ 203. 19022858
  37. [43]Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha‐synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115(4): 399‐ 407. 18297293 PMC2270355
  38. [44]Pletnikova O, West N, Lee MK, et al. Abeta deposition is associated with enhanced cortical alpha‐synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26(8): 1183‐ 1192. 15917102
  39. [46]Clinton LK, Blurton‐Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha‐synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30(21): 7281‐ 7289. 20505094 PMC3308018
  40. [47]Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta‐analysis. JAMA 2015; 313(19): 1939‐ 1949. 25988463 PMC4517678
  41. [48]Hsiao IT, Huang CC, Hsieh CJ, et al. Correlation of early‐phase 18F‐florbetapir (AV‐45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 2012; 39(4): 613‐ 620. 22270508

Cited by

Sorted by citations

Authors
Donaghy, P. C., Firbank, M. J., Thomas, A. J., Lloyd, J., Petrides, G., Barnett, N., Olsen, K., & O'Brien, J. T.
Affiliations
  • Newcastle University (GB)
  • National Health Service (GB)
  • University of Cambridge (GB)
Corresponding author
Donaghy, Paul C.
ORCID
Venue
Movement Disorders
Publisher
Wiley
Published
2018-04-19
Volume
33
Issue
7
Pages
1130-1138
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
DOI
10.1002/mds.27403
PMC
PMC6175485
OpenAlex
W2800500975
Cited by
52
References
5
Citations by year
2026: 2 · 2025: 8 · 2024: 4 · 2023: 8 · 2022: 5 · 2021: 3 · 2020: 12 · 2019: 7 · 2018: 3
FWCI
4.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Movement Disorders (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • NIHR
  • National Institute for Health Research (BH120812)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
dementia with Lewy bodies, amyloid deposition, florbetapir PET, cerebral perfusion, hippocampal volume, gray matter volume, cognitive impairment, functional disability
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Aniline Compounds, Brain, Cognition Disorders, England, Ethylene Glycols, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prospective Studies, Tomography Scanners, X-Ray Computed, Lewy Body Disease, Imaging, Three-Dimensional, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review